US Stocks Movement: VeraDermics surged on October 19: Phase III trial met targets + oral hair loss medication

VeraDermics October 19 Surge Interpretation

Keywords: phase III trial met targets, oral hair loss medication

1. On October 19, 2026, the company announced the topline results of VDPHL01 male pattern hair loss Phase III Study 304: 536 participants took part in the trial, and the study met all primary and secondary endpoints; after 6 months of treatment, the target area non-vellus hair count increased by 28.6 hairs/cm² and 36.4 hairs/cm² in the once-daily and twice-daily groups respectively, while the placebo group saw an increase of 6.6 hairs/cm². The differences were statistically significant.

2. On October 19, 2026, the company disclosed that as early as month 2 of the trial, VDPHL01 showed statistically significant differences compared to placebo in hair count, patient-reported outcomes, and investigator assessments; overall treatment tolerability was good, with no treatment-related serious adverse events or cardiovascular events of special interest observed.

(Disclaimer: This content is summarized from publicly available information collected using AI technology and is for reference only. It does not constitute investment advice.)